1. Scrip
  2. >>R&D
  3. >>Clinical Trials

BridgeBio Comes Back With Positive Phase III Results For Acoramidis In ATTR-CM

 
• By Alaric DeArment

The ATTRibute-CM study met its primary endpoint as well as key secondary endpoints, and the company plans to file for US FDA approval before the end of 2023.

BridgeBio announced data from its Phase III trial of acoramidis in ATTR-CM • Source: Shutterstock

BridgeBio Pharma, Inc.’s acoramidis found redemption, with the Phase III ATTRibute-CM showing positive results in transthyretin amyloid cardiomyopathy (ATTR-CM) as compared with the negative results at an interim analysis at the end of 2021. The positive Phase III data should carry the drug through to regulatory approval, but it may face commercial headwinds due to the entrenched position of Pfizer Inc.’s Vyndaqel/Vyndamax (tafamidis) franchise.

BridgeBio announced the ATTRibute-CM results on 17 July, stating that the study met its primary endpoint – consisting of a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.